A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease

Stephen Salloway, Martin R. Farlow, Eric McDade, David B. Clifford, Guoqiao Wang, Jorge J. Llibre‐Guerra, Janice M. Hitchcock, Susan L. Mills, Anna Santacruz, Andrew J. Aschenbrenner, Jason Hassenstab, Tammie L.S. Benzinger, Brian A. Gordon, Anne M. Fagan, Kelley A. Coalier, Carlos Cruchaga, Alison Goate, Richard J. Perrin, Chengjie Xiong, Yan Li, John C. Morris, B. Joy Snider, Catherine J. Mummery, Ghulam M. Surti, Didier Hannequin, David Wallon, Sarah Berman, James J. Lah, Ivonne Z. Jiménez‐Velázquez, Erik D. Roberson, Christopher H. van Dyck, Lawrence S. Honig, Raquel Sánchez‐Valle, William S. Brooks, Serge Gauthier, Douglas Galasko, Colin L. Masters, Jared R. Brosch, Ging‐Yuek Robin Hsiung, Suman Jayadev, Maïté Formaglio, Mario Masellis, Roger Clarnette, Jérémie Pariente, Bruno Dubois, Florence Pasquier, Clifford R. Jack, Robert A. Koeppe, Peter J. Snyder, Paul Aisen, Ronald G. Thomas, Scott Berry, Barbara Wendelberger, Scott W. Andersen, Karen C. Holdridge, Mark A. Mintun, R. Yaari, John R. Sims, Monika Baudler, Paul Delmar, Rachelle S. Doody, Paulo Fontoura, Caroline Giacobino, Geoffrey A. Kerchner, Randall J. Bateman, the Dominantly Inherited Alzheimer Network–Trials Unit, Maïté Formaglio, Susan L. Mills, Jérémie Pariente, Christopher H. van Dyck